Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Public Employees Retirement Association of Colorado Increases Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat

AI-generated analysis

πŸ“ˆ Public Employees Retirement Association of Colorado increased its stake by 1,037.2% to own 854,314 shares valued at $72.8 million.

πŸ’° The company reported Q4 EPS of $0.78 and revenue of $1.65 billion, beating consensus estimates.

πŸ“Š Institutional investors now hold 79.46% of the company's outstanding stock.

πŸ“‰ VP Daniel J. Lippis sold 1,019 shares and CFO Scott B. Ullem sold 13,000 shares recently under Rule 10b5-1 plans.

🎯 Analysts maintain a Moderate Buy consensus with an average price target of $95.96.

πŸ“‰ MarketBeat explicitly lists five other healthcare stocks as better buys than Edwards Lifesciences.

πŸ₯ The company focuses on structural heart disease products, including the SAPIEN family of transcatheter valves.

πŸ“ˆ FY 2026 EPS guidance is set between $2.95 and $3.05.

Bullish Signals
  • Public Employees Retirement Association of Colorado executed a massive 1,037.2% stake increase, signaling strong institutional confidence.
  • The company beat earnings estimates with $0.78 EPS and revenue of $1.65 billion.
  • Revenue grew 16.7% year-over-year to $1.65 billion.
  • Multiple hedge funds including Level Four Advisory Services LLC and McIlrath & Eck LLC increased their holdings.
  • Analysts maintain a Moderate Buy consensus with an average price target of $95.96.
  • Recent analyst upgrades from Wolfe Research, BTIG, and Mizuho reinforce positive sentiment.
Risk Factors
  • Insiders sold a total of 81,038 shares worth $6.68 million in the last three months.
  • MarketBeat explicitly states that Edwards Lifesciences was not included in their list of five preferred healthcare stocks for growth investors.
  • The stock is currently trading below its consensus price target of $95.96.
Full Analysis
Public Employees Retirement Association of Colorado dramatically increased its stake in Edwards Lifesciences (NYSE: EW) by 1,037.2% in the fourth quarter, purchasing an additional 779,187 shares to hold a total position valued at approximately $72.8 million. This significant move brings institutional ownership to 79.46%, while several other hedge funds also modestly raised their positions during the same period. Edwards Lifesciences reported strong quarterly financial results with earnings per share of $0.78 and revenue of $1.65 billion, both exceeding analyst estimates. The company maintains a Moderate Buy consensus among analysts with an average price target of $95.96, supported by recent upgrades from firms like Wolfe Research and BTIG. Despite the positive institutional activity and earnings beat, the article notes that insiders, including the VP and CFO, sold shares recently under pre-arranged trading plans. Additionally, MarketBeat explicitly states that EW was not included in their list of five preferred healthcare stocks for growth-minded investors, suggesting relative weakness compared to other sector picks.